<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Androl Urol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Androl Urol</journal-id><journal-id journal-id-type="publisher-id">TAU</journal-id><journal-title-group><journal-title>Translational Andrology and Urology</journal-title></journal-title-group><issn pub-type="epub">2223-4691</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4842508</article-id><article-id pub-id-type="publisher-id">tau-05-S1-AB098</article-id><article-id pub-id-type="doi">10.21037/tau.2016.s098</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>AB098. Can concomitant dutasteride reduce the effect of testosterone replacement therapy in men with late-onset hypogonadism? A 24-week, randomized, parallel study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Hyun Jun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moon</surname><given-names>Du Guen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Nam Cheol</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff><target id="aff1" target-type="aff"><sup>1</sup></target>Department of Urology, Pusan National University Hospital, Busan, <country>Korea</country>; <target id="aff2" target-type="aff"><sup>2</sup></target>Department of Urology, Korea University Hospital, Seoul, <country>Korea</country></aff></contrib-group><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>Suppl 1</issue><elocation-id>AB098</elocation-id><permissions><copyright-statement>2016 Translational Andrology and Urology. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Translational Andrology and Urology.</copyright-holder></permissions><abstract><sec><title>Objectives</title><p>5ARIs have sexual side effects, including erectile dysfunction (ED), loss of libido and ejaculatory dysfunction due to their action mechanism which decreases serum DHT levels. We examined whether concomitant dutasteride reduced the efficacy of testosterone replacement therapy (TRT) in men with late-onset hypogonadism.</p></sec><sec><title>Methods</title><p>This was a 24-week, randomized, parallel study of the clinical outcomes in men age &#x0003e;40 years with symptomatic benign prostatic hypertrophy [BPH; International Prostate Symptom Score (IPSS) th], prostate volume Prostate Symptom Score (IPSS) 300 ng/dL with aging male symptoms, who were taking stable doses of alpha-blockers 4 weeks before participation. Eligible patients received a combination of dutasteride 0.5 mg once daily and a transdermal gel containing 10 g testosterone (T) (DT group, n=30) or the transdermal gel alone (T group, n=30). The primary outcomes were the change in the aging male symptom (AMS) score, sexual desire (question 17, AMS score), and erectile function (International Index of Erectile Function-5). Secondary outcomes were the post-treatment IPSS, peak urinary flow rate, post-void residual urine volume (PVR), and prostate volume.</p></sec><sec><title>Results</title><p>Both groups showed significant improvements from baseline in all primary outcome parameters. However, there were no significant differences in the changes in the AMS total score (DT &#x02212;5.2 <italic>vs.</italic> T &#x02212;5.0; P=0.55), sexual desire (DT &#x02212;2.5 <italic>vs.</italic> T &#x02212;2.3; P=0.23), and IIEF-5 score (DT &#x02212;2.1 <italic>vs.</italic> T &#x02212;1.9; P=0.13) between groups. The extent of IPSS improvement from baseline to 24 weeks was the same in both groups (DT &#x02212;1.2 <italic>vs.</italic> T &#x02212;1.0; P=0.64). In addition, the changes in Q(max) and PVR from baseline were very similar in both groups. However, prostate volume decreased significantly (P&#x0003c;0.01) in the DT group (DT &#x02212;6.1 cc <italic>vs.</italic> T +0.6 cc).</p></sec><sec><title>Conclusions</title><p>Concomitant dutasteride did not reduce the effect of testosterone replacement therapy in men with late-2onset hypogonadism. Otherwise it would be helpful to prevent the progress of prostate size by TRT.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Erectile dysfunction</kwd><kwd>benign prostatic hypertrophy</kwd><kwd>testosterone replacement therapy</kwd></kwd-group></article-meta></front></article>